• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

Recent Advances in the Study of 5-amino-6-chloro-3,4-dihydropyrimidin-4-one (CAS: 3137-60-8): A Comprehensive Research Brief

5-amino-6-chloro-3,4-dihydropyrimidin-4-one (CAS: 3137-60-8) is a pyrimidine derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This compound serves as a key intermediate in the synthesis of various bioactive molecules, including antiviral and anticancer agents. Recent studies have explored its structural properties, synthetic pathways, and biological activities, shedding light on its versatility in drug development.

A study published in the Journal of Medicinal Chemistry (2023) investigated the role of 5-amino-6-chloro-3,4-dihydropyrimidin-4-one in the synthesis of novel nucleoside analogs with potent antiviral activity against RNA viruses. The researchers utilized a multi-step synthetic route, starting from commercially available precursors, to optimize the yield and purity of the target compound. Spectroscopic techniques, including NMR and mass spectrometry, were employed to confirm the structural integrity of the synthesized derivatives. The study reported promising in vitro results, with several analogs exhibiting low micromolar IC50 values against viral replication.

In another recent development, a research team from the University of Cambridge explored the anticancer potential of 5-amino-6-chloro-3,4-dihydropyrimidin-4-one derivatives. Their work, published in Bioorganic & Medicinal Chemistry Letters (2024), demonstrated that structural modifications of the core scaffold could enhance selectivity toward cancer cell lines while minimizing toxicity to normal cells. Molecular docking studies revealed that these derivatives interact with key oncogenic targets, such as protein kinases involved in cell proliferation pathways. The findings suggest that further optimization of this compound class could lead to the development of targeted cancer therapies.

The pharmaceutical industry has also shown growing interest in 5-amino-6-chloro-3,4-dihydropyrimidin-4-one as a building block for drug discovery. A patent application filed in 2024 by a major biotech company describes novel synthetic methods for large-scale production of this intermediate, addressing previous challenges in yield and scalability. The improved synthetic protocol employs green chemistry principles, reducing the environmental impact of the manufacturing process while maintaining high purity standards required for pharmaceutical applications.

From a mechanistic perspective, recent computational studies have provided insights into the molecular interactions of 5-amino-6-chloro-3,4-dihydropyrimidin-4-one with biological targets. Quantum mechanical calculations and molecular dynamics simulations have elucidated the compound's electronic properties and conformational flexibility, which are crucial for understanding its binding affinity with various enzymes and receptors. These computational approaches are proving valuable in guiding the rational design of more potent derivatives.

Looking ahead, researchers are focusing on expanding the therapeutic applications of 5-amino-6-chloro-3,4-dihydropyrimidin-4-one beyond its current scope. Preliminary studies suggest potential utility in neurodegenerative diseases and inflammatory conditions, opening new avenues for drug development. However, challenges remain in optimizing pharmacokinetic properties and overcoming potential metabolic instability observed in some derivatives. Continued research efforts are needed to translate these promising findings into clinically viable therapeutic agents.

• 45864-28-6(4(1H)-Pyrimidinone,2,5,6-triamino-1-methyl-)
• 14675-49-1(4(3H)-Pyrimidinone,5-amino-6-methyl-)
• 61693-35-4(4(1H)-Pyrimidinone, 5-amino-2-(dimethylamino)-6-(methylamino)-)
• 61693-30-9(4(1H)-Pyrimidinone, 2,5-diamino-6-(dimethylamino)-)
• 61693-25-2(4(1H)-Pyrimidinone, 5,6-diamino-2-(methylamino)-)
• 61595-47-9(4(1H)-Pyrimidinone, 5-amino-2-(dimethylamino)-6-methyl-)
• 61595-46-8(4(1H)-Pyrimidinone, 5-amino-6-methyl-2-(methylamino)-)
• 36755-72-3(4(3H)-Pyrimidinone,6-amino-5-nitroso-)
• 61693-31-0(4(1H)-Pyrimidinone, 5,6-diamino-2-(dimethylamino)-)
• 77994-14-0(4(3H)-Pyrimidinone,5-amino-2-(methylamino)-)